Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 deaths 0.33 [0.16, 0.69]< 1 0% 4 studies (4/-) 99.8 % high not evaluable low crucial - clinical deterioration 0.45 [0.26, 0.80]< 1 0% 3 studies (3/-) 99.7 % high not evaluable low important - clinical improvement 1.67 [1.05, 2.66]> 1 0% 3 studies (3/-) 98.5 % high not evaluable low important - clinical improvement (7-day) 1.82 [1.23, 2.69]> 1 0% 2 studies (2/-) 99.9 % high not evaluable low important - clinical improvement (time to event analysis only) 1.89 [1.06, 3.38]> 1 0% 1 study (1/-) 98.4 % high not evaluable low important - PCR-negative conversion 0.92 [0.77, 1.09]> 1 0% 2 studies (2/-) 16.4 % high not evaluable low important - PCR-negative conversion (14-day) 4.10 [1.12, 14.99]> 1 0% 1 study (1/-) 98.3 % high not evaluable low important - PCR-negative conversion (7-day) 0.92 [0.77, 1.09]> 1 0% 1 study (1/-) 17.3 % low not evaluable high important - PCR-negative conversion (time to event analysis only) 4.10 [1.12, 14.99]> 1 0% 1 study (1/-) 98.3 % high not evaluable low important - ventilation 0.42 [0.02, 7.39]< 1 0% 1 study (1/-) 72.0 % some concern not evaluable moderate important - 00 serious adverse events 2.14 [0.21, 21.56]< 1 0% 2 studies (2/-) 26.0 % high not evaluable low important - adverse events 1.97 [0.55, 7.04]< 1 36% 3 studies (3/-) 15.0 % high not evaluable low non important -
LoD: level of demonstration (
